Compare Cassava Sciences Inc (FLNA) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Xylem, Inc. — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Xylem, Inc. trades at $121.6 (market cap $28.86B). The key difference: Xylem, Inc. is far larger — about 543.1× Cassava Sciences Inc's market cap, and Xylem, Inc. pays a 1.42% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | XYL | |
|---|---|---|
Market Cap | $53.14M | $28.86B |
Sector | Health | Industrials |
52-Week High | $4.64 | $152.95 |
52-Week Low | $1.09 | $106.34 |
Enterprise Value | -$33.43M | $30.12B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Xylem (XYL) trades at $125.26, up 3.05% over 24 hours, with a bullish technical signal and consistent earnings beats. Revenue grew from $5.5B in 2022 to $9.0B in 2025, with net margins expanding to 10.59%. Recent news highlights partnerships, leadership appointments, and a dividend declaration, reinforcing its position in water technology solutions.
Outlook remains positive with a consensus price target of $152, implying 21% upside. Risks include execution challenges and macroeconomic pressures, but strong cash flow and analyst support suggest long-term growth potential for investors focused on sustainable infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
